Plain-English translation of NCT05983250 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called levosimendag to see if it can help people who have high blood pressure in their lungs as a result of a specific type of heart failure. The study will compare the medication to a placebo (a pill with no active ingredient) to learn whether the treatment improves exercise ability and reduces symptoms. About 230 people will participate in this 12-week study.
This type of heart condition—high blood pressure in the lungs combined with heart failure—is difficult to treat with current medications, and patients often struggle with exercise limitations and fatigue. Researchers believe this medication might help by improving how the heart works and reducing the strain on the lungs.
You likely qualify if…
You likely don't qualify if…
You'll first go through a screening period of up to 30 days, during which you'll have heart imaging, breathing tests, and heart rhythm monitoring to confirm you qualify. If you do, you'll be randomly assigned to take either the new medication or a placebo once daily for 12 weeks, and you'll visit the clinic for check-ups during that time. After the 12 weeks, you'll have the option to continue in an extended study for up to 92 additional weeks if you wish.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States